Tagged with B

Biosano “A company active in the Chilean pharmaceutical market has to reinvent its business model every three years because today we are competing against some of the largest multinationals.”     How has the company developed over the past years? Chile has a very open and transparent market, which requires companies to…

mergers The global pharmaceutical sector continues to witness significant mergers and acquisitions activity, with 122 M&A deals completed in 2013. This trend has continued due to several multi-billion dollar deals around the world in 2014, which is already recorded the busiest year for healthcare acquisitions. In Chile, the dealmaking sweeping started in December 2013…

Biotechnology Merck’s managing director discusses the importance of diversification to succeed in Poland by saying: “Nowadays, in such a dynamic environment the healthy level of diversification that Merck offers is becoming a critical factor for sustainable growth.” Despite the fact that the Polish business environment has changed significantly, access to innovation…

Generics The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the positive and negative aspects of the new legislative framework implemented in January 2012? The positive aspects of the Reimbursement Act…

Generics The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the positive and negative aspects of the new legislative framework implemented in January 2012? The positive aspects of the Reimbursement Act…

Generics The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the positive and negative aspects of the new legislative framework implemented in January 2012? The positive aspects of the Reimbursement Act…

diabetes PMG Pharma, a niche player, with products concentrated in the nephrology/dialysis, injectables and diabetes areas, has concluded distribution agreements with companies from all over the world. “Many are underestimating the Chinese pharmaceutical market but I expect to see a lot of business coming from that country”, tells Horst Peter Endler…

Canada This graph shows Quebec’s R&D expenditure as a percentage of GDP, in comparison to other provinces in Canada, as well as other OECD countries.

chronic pain Bene Farmacêutica was established in 2009 to expand the supply and presence of Bene-Arzneimittel in Portugal, having already sold products in the country for several decades. The affiliate’s managing director, Frank Tischler, outlines Bene Farmacêutica’s entrance into Portugal and discusses the importance of adding value to brands in an environment…

Infarmed Eurico Castro Alves, president of Portugal’s regulatory agency Infarmed, talks about the biggest challenges facing the regulation of health products in the country today, and introduces new initiatives aimed at positioning Infarmed as a regulator of reference worldwide.   You have been president of Infarmed since 2012. What have been some…

biotech Portuguese pharmaceutical group Bluepharma consists of ten companies that represent different parts of the medicine value chain. The success of Bluepharma during Portugal’s crisis was due to a strong focus on overseas exports and diversification of risk. Paulo Barradas and Sérgio Simões explain how they created that success.   Bluepharma…

biotech Portuguese pharmaceutical group Bluepharma consists of ten companies that represent different parts of the medicine value chain. The success of Bluepharma during Portugal’s crisis was due to a strong focus on overseas exports and diversification of risk. Paulo Barradas and Sérgio Simões explain how they created that success.   Bluepharma…